摘要
目的通过多中心、随机、对照f临床研究，观察血必净注射液对急性呼吸窘迫综合征（ARDS）患者免疫功能及预后的影响。方法采用前瞻性研究方法，将2008年1月至2010年7月江苏省10家三级医院综合重症医学科（ICU）连续收治的ARDS患者按随机原则分为血必净组（91例）和对照组（81例）。对照组按照常规方法治疗；血必净组在常规治疗基础上加用血必净注射液100ml静脉滴注、每日2次，治疗7d。检测外周血人白细胞DR抗原（HLA—DR）和T淋巴细胞亚群（CD4＋、CD8＋）水平变化，以28d病死率为主要评价指标。结果血必净组治疗后CD8＋高于对照组（0．39±0．13比0．30±0．12，P〈0．05），而CD4＋、HLA—DR与对照组比较差异均无统计学意义[CD4＋：0．51±0．13比0．50±0．17，HLA—DR：（43．8±16．O）％1：t（45．1±23．0）％，均P〉0．05]。血必净组肺内源性ARDS患者28d病死率明显低于对照组（23．2％比40．7％，P〈0．05）。结论血必净注射液可能通过调节机体免疫状态，改善肺内源性ARDS患者的预后。
Objective To study the effect of Xuebijing injection treatment on immune function and prognosis of patients with acute respiratory distress syndrome （ ARDS ） by a prospective multicenter randomized clinical research. Methods From January 2008 to July 2010, a clinical study was conducted on consecutive adult patients with ARDS in intensive care units （ ICUs ） of ten Jiangsu Provincial hospitals of the third grade, and they were divided into two groups： Xuebijing group （ 91 cases ） and control groups （ 81 cases ） . Both groups were treated by routine therapy of ARDS, while in Xuebijing group, Xuebijing injection was additionally used, 100 ml twice a day for 7 days. The human leukocyte DR antigen （ HLA-DR ） and subpopulations of T-lymphocytes （ CD4＋, CD8＋ ） in peripheral blood were detected, respectively. A period of 28 days was used as the main evaluate index of the mortality of patients with ARDS. Results The plasma level of CD8＋ in treatment group （0.39±0.13 vs. 0.30±0.12, P〈 0.05） was higher than that in control group after treatment, but there was no significant difference in the plasma level of CD4＋ and HLA-DR between two groups [ CD4＋： 0.51±0.13 vs. 0.50±0.17, HLA-DR： （43.8± 16.0） % vs. （45.1±23.0 ） %, both P〉0.05 3 ; the mortality in 28 days of treatment group （23.2%） was less than that of control group （ 40.7% , P〈0.05 ）. Conclusion Xuebijing injection improves the prognosis of patients with ARDS caused by pulmonary diseases through adjusting immune function of the organism.
出处
《中国中西医结合急救杂志》
CAS
北大核心
2012年第1期21-23,共3页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
基金
天津市科委科技创新基金资助项目（778590003032）
江苏省基础研究计划（BK2010086）
关键词
血必净注射液
急性呼吸窘迫综合征
免疫功能
预后
Xuebijing injection
Acute respiratory distress syndrome
Immune function
Prognosis
